Latest Oncology News

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

November 20th 2024

Ryan Scott

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

November 20th 2024

Courtney Flaherty

Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

November 20th 2024

D. Ross Camidge, MD, PhD

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

November 20th 2024

Courtney Flaherty

Zorifertinib has received NMPA approval in the first line for EGFR-mutant advanced or metastatic non–small cell lung cancer displaying CNS metastases.

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

November 20th 2024

Caroline Seymour

The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.

Latest Oncology Videos

Overview of PERSEUS, IsKia, and GMMG-HD7
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice
Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV
Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
Looking Ahead and Key Takeaways
Optimizing Regimens and Managing Adverse Events in TIE NDMM
Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy
Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease
Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLL
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL
Dr Sharma on the Impact of Frontline Treatment Advances in Advanced Bladder Cancer
Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC
Treatment Sequencing in Relapsed/Refractory CLL: Key Factors Influencing Decision-Making

All Oncology News

Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer

November 20th 2024

Fox Chase Cancer Center

Parth A. Desai, MBBS, MD, was first author on a study that detailed significant findings in small cell lung cancer.

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

November 20th 2024

Maurie Markman, MD

Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

November 20th 2024

Courtney Flaherty

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

CDK4/6 Inhibitors, Targeted Therapies May Expand Their Reach in HR+ Metastatic Breast Cancer

November 19th 2024

Ashling Wahner

Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer

November 19th 2024

Ryan Scott

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Roswell Park Team Members Recognized for Exceptional Support to First Responders

November 19th 2024

Roswell Park Comprehensive Cancer Center

Nurse-executive and partnership manager honored for dedication to local heroes.

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

November 19th 2024

Ryan Scott

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

Chris Ryan

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rate in BCG-Unresponsive NMIBC With CIS

November 19th 2024

Chris Ryan

Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.

MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors

November 19th 2024

Kyle Doherty

Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

November 19th 2024

Chris Ryan

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

November 19th 2024

Jax DiEugenio

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

November 19th 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

This episode reviews the response rates reported in the HERTHENA-Lung01 trial among patients with advanced NSCLC exhibiting various resistance mechanisms, evaluates the clinical significance of responses to HER3-DXd based on HER3 expression scores, discusses the relevance of the reported overall DOR, median PFS, and OS, and examines the CNS ORR among patients with baseline brain metastases in relation to the ORRs.

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

November 18th 2024

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

Dr Sharma on the CheckMate 901 Study in Advanced Urothelial Cancer

November 18th 2024

Janaki Neela Sharma, MD

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

See All News